A multi-cohort randomized Phase 2 open-label study to assess the preliminary efficacy safety and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Antibody-mediated Rejection
  • Age: Between 18 Year(s) - 75 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:

    Cohort A:
    1. Contraceptive use by men and women should be consistent methods of contraception for those participating in clinical studies.
    2. Participants

You may not be eligible for this study if the following are true:

    1. History of severe cardiac disease such as chronic heart failure III-IV, myocardial infarction =6 months of enrollment, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular dis


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.